Market Place
Sourcing Support
Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® in mIDH1 AML
05 Sep 2024 //
PR NEWSWIRE
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
06 Aug 2024 //
PR NEWSWIRE
Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients
04 Apr 2024 //
PR NEWSWIRE
Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
04 Jan 2024 //
PR NEWSWIRE
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance
08 Dec 2023 //
PR NEWSWIRE
Rigel Announces Presentation of Data from Analysis of REZLIDHIA
07 Jun 2023 //
PR NEWSWIRE
Rigel Announces Publication of REZLIDHIA Phase 2 Results in Blood Advances
02 Feb 2023 //
PR NEWSWIRE
National Comprehensive Cancer Network Adds REZLIDHIA to Practice Guidelines
18 Jan 2023 //
PR NEWSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Rigel wins US approval of rival drug to Servier leukemia treatment
03 Dec 2022 //
BIOPHARMADIVE
FDA approves Rezlidhia™ for leukaemia
02 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
U.S. FDA approves Rigel Pharma`s treatment for a type of leukemia
02 Dec 2022 //
REUTERS
Rigel and Forma enter licence deal for acute myeloid leukaemia therapy
03 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
Rigel and Forma Announce Licensing Agreement for Olutasidenib in r/r AML
02 Aug 2022 //
PRNEWSWIRE
Forma`s Olutasidenib+Azacitidine Yields Durable Complete Remission in mIDH1 AML
16 Dec 2021 //
BUSINESSWIRE
Forma Therapeutics Announces Four Presentations on Etavopivat ASH
04 Nov 2021 //
BUSINESSWIRE
Forma takes aim at Agios with new AML complete remission data
26 Oct 2020 //
ENDPTS
Forma Therapeutics Announces Clinical Data to be Presented at ASCO20
28 May 2020 //
BUSINESSWIRE
FORMA Therapeutics Announces +ve Preliminary Ph1/2 IDH1m Inhibitor Olutasidenib
09 Dec 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.